Cambridge University Hospitals, Cambridge, UK.
International Medical School, Tor Vergata University of Rome, Rome, Italy.
Eur Urol. 2023 Mar;83(3):249-256. doi: 10.1016/j.eururo.2022.12.007. Epub 2023 Jan 4.
Prostate magnetic resonance imaging (MRI) is now standard for assessment of suspected prostate cancer (PCa). A variety of approaches to MRI-based targeting has revolutionised prostate biopsies.
To describe the procedure and show the accuracy and tolerability of a novel Vector MRI/ultrasound fusion transperineal (TP) biopsy technique that uses electromagnetic (EM) needle tracking under local anaesthesia (LA).
DESIGN, SETTING, AND PARTICIPANTS: Vector prostate biopsy using BiopSee fusion software, EM tracking technology, and transrectal ultrasound was performed in 69 patients meeting the biopsy criteria in two UK centres between September 2020 and August 2022.
Stepper-mounted rectal ultrasound images were fused with MRI scans. LA was applied into two defined perineal tracks and a needle sheath with an EM sensor was inserted. The biopsy needle was directed precisely through the sheath to MRI targets under EM tracking. Biopsies were taken without antibiotic prophylaxis.
Cancer detection (any PCa; grade group ≥2), side effects, and patient experience measures were recorded.
Cancer detection in patients with Likert 4-5 lesions was 98% for any PCa and 83% for grade group ≥2. According to the 50 questionnaires returned, 42 patients (84%) reported no or minimal pain, while 40 (80%) reported no or minimal discomfort. No episodes of postoperative urinary retention occurred, and only one patient required treatment for infection. Limitations include the low patient number and incomplete responses to questionnaires.
This novel Vector technique provides a feasible and tolerable procedure for MRI/ultrasound fusion TP biopsy under LA, with high cancer detection rates. This is achieved while maintaining patient comfort and with minimal rates of complications.
We report a novel technique that uses electromagnetic needle tracking to perform highly accurate and comfortable prostate biopsies through the perineum under local anaesthetic.
前列腺磁共振成像(MRI)现在是评估疑似前列腺癌(PCa)的标准方法。各种基于 MRI 的靶向方法彻底改变了前列腺活检。
描述一种新的基于向量的 MRI/超声融合经会阴(TP)活检技术的操作过程,并展示其准确性和耐受性,该技术在局部麻醉(LA)下使用电磁(EM)针跟踪。
设计、地点和参与者:2020 年 9 月至 2022 年 8 月,在英国的两个中心,符合活检标准的 69 名患者使用 BiopSee 融合软件、EM 跟踪技术和经直肠超声进行了 Vector 前列腺活检。
将步进式直肠超声图像与 MRI 扫描融合。在两个定义的会阴轨道中应用 LA,并插入带有 EM 传感器的针鞘。在 EM 跟踪下,活检针在 EM 跟踪下精确地穿过鞘到达 MRI 靶标。未预防性使用抗生素进行活检。
记录癌症检出率(任何 PCa;分级组≥2)、副作用和患者体验指标。
在具有 Likert 4-5 病变的患者中,任何 PCa 的癌症检出率为 98%,分级组≥2 的癌症检出率为 83%。根据返回的 50 份问卷,42 名患者(84%)报告无或轻微疼痛,而 40 名患者(80%)报告无或轻微不适。没有发生术后尿潴留,只有 1 名患者需要治疗感染。局限性包括患者数量少和问卷调查的回复不完整。
这种新的 Vector 技术为在 LA 下进行 MRI/超声融合 TP 活检提供了一种可行且可耐受的方法,具有较高的癌症检出率。在保持患者舒适度的同时,并发症发生率最低。
我们报告了一种新的技术,它使用电磁针跟踪在 LA 下通过会阴进行高度准确和舒适的前列腺活检。